Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Oramed Pharmaceuticals (ORMP) stock

Learn how to easily invest in Oramed Pharmaceuticals stock.

Oramed Pharmaceuticals Inc is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Oramed Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORMP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oramed Pharmaceuticals stock price (NASDAQ: ORMP)

Use our graph to track the performance of ORMP stocks over time.

Oramed Pharmaceuticals shares at a glance

Information last updated 2021-07-22.
Latest market close$11.52
52-week range$2.40 - $15.17
50-day moving average $13.30
200-day moving average $10.15
Wall St. target price$22.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.87

Buy Oramed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oramed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oramed Pharmaceuticals price performance over time

Historical closes compared with the close of $11.52 from 2021-05-28

1 week (2021-07-14) N/A
1 month (2021-06-25) -14.48%
3 months (2021-04-21) N/A
6 months (2021-01-21) N/A
1 year (2020-07-21) N/A
2 years (2019-07-21) N/A
3 years (2018-07-21) N/A
5 years (2016-07-21) N/A

Oramed Pharmaceuticals financials

Revenue TTM $2.7 million
Gross profit TTM $2.7 million
Return on assets TTM -19.57%
Return on equity TTM -36.39%
Profit margin 0%
Book value $2.23
Market capitalisation $424.6 million

TTM: trailing 12 months

Shorting Oramed Pharmaceuticals shares

There are currently 2.4 million Oramed Pharmaceuticals shares held short by investors – that's known as Oramed Pharmaceuticals's "short interest". This figure is 10.5% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Oramed Pharmaceuticals shares can be evaluated.

Oramed Pharmaceuticals's "short interest ratio" (SIR)

Oramed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Oramed Pharmaceuticals shares currently shorted divided by the average quantity of Oramed Pharmaceuticals shares traded daily (recently around 632368.78306878). Oramed Pharmaceuticals's SIR currently stands at 3.78. In other words for every 100,000 Oramed Pharmaceuticals shares traded daily on the market, roughly 3780 shares are currently held short.

However Oramed Pharmaceuticals's short interest can also be evaluated against the total number of Oramed Pharmaceuticals shares, or, against the total number of tradable Oramed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oramed Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Oramed Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0796% of the tradable shares (for every 100,000 tradable Oramed Pharmaceuticals shares, roughly 80 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oramed Pharmaceuticals.

Find out more about how you can short Oramed Pharmaceuticals stock.

Oramed Pharmaceuticals share dividends

We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.

Have Oramed Pharmaceuticals's shares ever split?

Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.

Oramed Pharmaceuticals share price volatility

Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $2.4 up to $15.17. A popular way to gauge a stock's volatility is its "beta".

ORMP.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.9086. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oramed Pharmaceuticals overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006.

Oramed Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

What percentage of Oramed Pharmaceuticals is owned by insiders or institutions?
Currently 9.52% of Oramed Pharmaceuticals shares are held by insiders and 10.159% by institutions.
When does the fiscal year end for Oramed Pharmaceuticals?
Oramed Pharmaceuticals's fiscal year ends in August.
Where is Oramed Pharmaceuticals based?
Oramed Pharmaceuticals's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036
What is Oramed Pharmaceuticals's ISIN number?
Oramed Pharmaceuticals's international securities identification number is: US68403P2039
What is Oramed Pharmaceuticals's CUSIP number?
Oramed Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 68403P104

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site